A Phase 3, single-arm, multicenter, multinational, open label,one-way crossover study to investigate the efficacy and safety of fitusiran prophylaxis in male participants aged ≥ 12 years with severe hemophilia A or B, with or without inhibitory antibodies to factor VIII or IX

drug protocol number

EFC17574

drug sponsor

Sanofi

drug study

Fitusiran

drug trial site

King Faisal Specialist Hospital and Research Center (Riyadh) , King Abdulaziz University Hospital (Jeddah)

drug status

Ongoing

drug phase